Rocket Pharmaceuticals, Inc. (RCKT) Discusses Danon Disease Program Update With Focus on RP-A501 Pivotal Trial and Preliminary Clinical Data Transcript

Rocket Pharmaceuticals, Inc. (RCKT) provided an update on its Danon disease program, focusing on the RP-A501 pivotal trial and preliminary clinical data.

The company reported positive interim data from the trial, with all three patients achieving a significant reduction in left ventricular mass.

Rocket also announced plans to present additional data at the upcoming European Society of Cardiology Congress.